Dr Reddy's Laboratories Ltd Product Launch
DRREDDY Obeda® (2mg/4mg Semaglutide injection, GLP-1 agonist) launched March 21, 2026, at ₹4,200/month; first Indian firm with DCGI nod. Phase-III proven non-inferior; expands diabetes portfolio.
#FundamentalViews#WatchOutFor#StockInNews
481 likes·46 comments